Halozyme Therapeutics, Inc.(HALO)Earnings, Financials & Key RatiosHalozyme Therapeutics, Inc. (HALO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the forward P/E of 9.24 suggests potential undervaluation, the elevated debt-to-equity ratio of 9.76 and reliance on milestone-driven cash flows warrant a cautious approach to long-term capital appreciation.
Halozyme Therapeutics, Inc. (HALO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Halozyme Therapeutics, Inc. (HALO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $1.60vs $1.55+3.2% | $377Mvs $359M+5.0% |
| Q1 2026 | Feb 17, 2026 | $0.24vs $2.15-111.2% | $452Mvs $436M+3.7% |
| Q4 2025 | Nov 3, 2025 | $1.72vs $1.63+5.5% | $354Mvs $447M-20.7% |
| Q3 2025 | Aug 5, 2025 | $1.54vs $1.23+25.2% | $326Mvs $331M-1.5% |
Recent stock market news and headlines for Halozyme Therapeutics, Inc. (HALO)
SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created role, Mr.
Key metrics vs top competitors for Halozyme Therapeutics, Inc. (HALO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $81.57 | $9.68B | 31.86 | 37.55% | 22.69% | 153.59% | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $57.08 | $14.5B | 20.53 | 6.98% | 35.08% | 40.21% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — |
Halozyme Therapeutics, Inc. (HALO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Halozyme Therapeutics, Inc. (HALO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
May 7, 2026·SEC
Apr 30, 2026·SEC
Get notified when HALO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Halozyme Therapeutics, Inc. (HALO) stock FAQ — growth, dividends, profitability & financials explained
Halozyme Therapeutics, Inc. (HALO) reported $1.51B in revenue for fiscal year 2025. This represents a 6110728% increase from $0.0M in 2001.
Halozyme Therapeutics, Inc. (HALO) grew revenue by 37.6% over the past year. This is strong growth.
Yes, Halozyme Therapeutics, Inc. (HALO) is profitable, generating $348.8M in net income for fiscal year 2025 (22.7% net margin).
Halozyme Therapeutics, Inc. (HALO) has a return on equity (ROE) of 153.6%. This is excellent, indicating efficient use of shareholder capital.
Halozyme Therapeutics, Inc. (HALO) generated $667.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
